Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients

Clinical and Experimental Rheumatology

Volumn 28, Issue 5, 2010, Pages 782-789

  Mathiesen, P R ^a   Zak, M ^b   Herlin, T ^c   Nielsen, S M ^b  

^a Mental Health Center Glostrup   (Denmark)

^b University of Copenhagen   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Calcinosis; Juvenile dermatomyositis; Myositis damage index; Outcome assessments

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE;

ARTHRALGIA; ARTICLE; CALCINOSIS; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DYSPHAGIA; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; JUVENILE DERMATOMYOSITIS; LIPODYSTROPHY; LUNG FUNCTION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYALGIA; OSTEOPOROSIS; PAPULE; PHYSIOTHERAPY; PRIORITY JOURNAL; RASH; REMISSION; RETROSPECTIVE STUDY; SKIN ULCER; WEIGHT REDUCTION;

ADOLESCENT; CALCINOSIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DERMATOMYOSITIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LUNG DISEASES; MALE; MEDICAL RECORDS; MYOSITIS; OSTEOPOROSIS; REGISTRIES; REMISSION INDUCTION; TIME FACTORS;

EID: 78650573251     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. PILKINGTON CA, WEDDERBURN LR: Paediatric idiopathic inflammatory muscle disease: recognition and management. Drugs 2005;65:1355-65.
2. FELDMAN BM, RIDER LG, REED AM, PACHMAN LM: Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12.
3. HUBER A, FELDMAN BM: Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 2005;7:441-6.
4. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
5. BOHAN A, PETER JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
6. BROWN VE, PILKINGTON CA, FELDMAN BM, DAVIDSON JE: An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford) 2006;45:990-3.
7. ISENBERG DA, ALLEN E, FAREWELL V et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004;43:49-54.
8. RUPERTO N, RAVELLI A, PISTORIO A et al.: The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008;59:4-13.
9. MCCANN LI, JUGGINS AD, MAILLARD SM et al.: The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) - clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006;45:1255-60.
10. MENDEZ EP, LIPTON R, RAMSEY-GOLDMAN R et al.: US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003;49:300-5.
11. HUBER AM, LANG B, LEBLANC CM et al.: Medium-and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-9.
12. PACHMAN LM, HAYFORD JR, CHUNG A et al.: Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998;25:1198-204.
13. RAVELLI A, TRAIL L, FERRARI C et al.: Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 2010;62:63-72.
14. RIDER LG, LACHENBRUCH PA, MONROE JB et al.: Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009;60:3425-35.
15. SANNER H, GRAN JT, SJAASTAD I, FLATØ B: Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology 2009;48:1541-7.
16. PACHMANN LM, LIPTON R, RAMSEY-GOLDMAN R et al.: History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Muskuloskeletal and Skin Diseases Research registry. Arthritis Rheum 2005;53:166-72.
17. FISLER RE, LIANG MG, FUHLBRIGGE RC, YALCINDAG A, SUNDEL RP: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
18. TSE S, LUBELSKY S, GORDON M et al.: The arthritis of inflammatory childhood myositis syndromes. J Rheumatol 2001;28:192-7.
19. TRAPANI S, CAMICIOTTOLI G, VIERUCCI A, PISTOLESI M, FALCINI F: Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study. Rheumatology (Oxford) 2001;40:216-20.
20. KOBAYASHI I, YAMADA M, TAKAHASHI Y et al.: Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporine A. Rheumatology (Oxford) 2003;42:371-4.